Poseida Therapeutics, Inc. (PSTX)
NASDAQ: PSTX · IEX Real-Time Price · USD
3.190
-0.155 (-4.63%)
May 17, 2024, 4:00 PM EDT - Market closed
Poseida Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for PSTX stock have an average target of 14.67, with a low estimate of 10 and a high estimate of 20. The average target predicts an increase of 359.87% from the current stock price of 3.19.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for PSTX stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 1 | 1 | 1 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +526.96% | May 2, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +526.96% | Apr 22, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +526.96% | Mar 8, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $8 → $10 | Buy | Maintains | $8 → $10 | +213.48% | Dec 11, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $15 → $20 | Strong Buy | Maintains | $15 → $20 | +526.96% | Dec 11, 2023 |
Financial Forecast
Revenue This Year
47.60M
from 64.70M
Decreased by -26.43%
Revenue Next Year
28.90M
from 47.60M
Decreased by -39.29%
EPS This Year
-1.70
from -1.37
EPS Next Year
-1.84
from -1.70
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 63.0M | 47.3M | n/a | 80.3M | 398.4M |
| Avg | 47.6M | 28.9M | n/a | 66.9M | 237.0M |
| Low | 29.4M | 9.8M | n/a | 53.6M | 83.6M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.6% | -0.7% | - | - | 495.3% |
| Avg | -26.4% | -39.3% | - | - | 254.2% |
| Low | -54.6% | -79.4% | - | - | 24.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.32 | -1.29 | -0.89 | -1.22 | 0.29 |
| Avg | -1.70 | -1.84 | -1.36 | -1.19 | -0.16 |
| Low | -2.02 | -2.44 | -1.78 | -1.15 | -0.58 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.